Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/22242
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKaba, S. E.en
dc.contributor.authorDeMonte, F.en
dc.contributor.authorBruner, J. M.en
dc.contributor.authorKyritsis, A. P.en
dc.contributor.authorJaeckle, K. A.en
dc.contributor.authorLevin, V.en
dc.contributor.authorYung, W. K.en
dc.date.accessioned2015-11-24T19:23:05Z-
dc.date.available2015-11-24T19:23:05Z-
dc.identifier.issn0148-396X-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22242-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectBrain/pathologyen
dc.subjectDose-Response Relationship, Drugen
dc.subjectDrug Administration Scheduleen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectInjections, Subcutaneousen
dc.subjectInterferon-alpha/*administration & dosage/adverse effectsen
dc.subjectMagnetic Resonance Imagingen
dc.subjectMaleen
dc.subjectMeningeal Neoplasms/pathology/*therapyen
dc.subjectMeningioma/pathology/*therapyen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Recurrence, Local/pathology/*therapyen
dc.subjectNeoplasm Stagingen
dc.subjectRecombinant Proteinsen
dc.subjectTreatment Outcomeen
dc.titleThe treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2Ben
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/9007858-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1997-
heal.abstractOBJECTIVE: Recurrent malignant meningiomas and unresectable meningiomas represent a great therapeutic challenge after the failure of radiation therapy. No effective chemotherapy has been found. We report the preliminary results of the treatment of patients with recurrent unresectable or malignant meningiomas with recombinant interferon alpha-2B (IFN-alpha-2B). METHOD: Each of six patients with either a recurrent malignant meningioma or an unresectable meningioma was treated with IFN-alpha, administered subcutaneously at a dosage of 4 mU/m2 per day, 5 days per week. Two of the six meningiomas were regular, one was atypical, and three were malignant. RESULTS: Five of six patients exhibited positive response to treatment; with stabilization of the size of the tumor in four patients and slight regression in one. The responses observed lasted from 6 to 14 months. The toxicity associated with prolonged use of IFN-alpha was mild and well tolerated. CONCLUSION: These results suggest that IFN-alpha is effective in the treatment of recurrent malignant meningiomas.en
heal.journalNameNeurosurgeryen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons